摘要目的:评价25 G微创玻璃体切除联合地塞米松玻璃体植入剂傲迪适(ozurdex)治疗视网膜静脉阻塞继发黄斑前膜及黄斑水肿的临床效果。方法:回顾性分析2019年1月至2020年6月郑州市第二人民医院视网膜分支静脉阻塞继发黄斑前膜及黄斑水肿应用25 G微创玻璃体切除术联合傲迪适植入治疗的30例(30眼)的临床资料。术后随访6个月以上。观察治疗前后视力、黄斑中心区视网膜厚度(CMT)及并发症。结果:治疗前视力(BCVA，logMAR)为0.87±0.63，治疗后各时间点之间视力与治疗前的差异均有统计学意义( F＝1.434， P<0.001)，治疗后各时间点之间视力差异均无统计学意义( P>0.05)；治疗前CMT为(638.59±198. 46)μm，治疗后各时间点均较治疗前明显降低( F＝24.79， P<0.05)，而且大致上呈逐渐降低的趋势。随访期间有11眼(36.67%)黄斑水肿复发，复发时间为(3.27±0.65)个月，未发生眼部或全身严重并发症。 结论:玻璃体切除术联合地塞米松玻璃体植入剂治疗视网膜静脉阻塞继发黄斑前膜及黄斑水肿，可有效减轻水肿并提高视力。

abstractsObjective:To evaluate the clinical efficacy of 25 G vitrectomy assisted with intravitreal implant of dexamethasone (Ozurdex) for the treatment of macular edema and macular epiretinal membrane secondary to retinal vein occlusion.Methods:This was a retrospective series case study. The clinical data of 30 eyes of 30 cases with macular edema and macular epiretinal membrane secondary to retinal vein occlusion with treated with 25 G vitrectomy assisted with intravitreal implant of Ozurdex from Jan. 2019 to Jun. 2020 in Zhengzhou Municipal Second People’s Hospital were analyzed. All patients were followed up for more than 6 months. The visual acuity and the central macular thickness (CMT) before and after implantation, as well as the complications were observed.Results:The visual acuity (BCVA, logMAR) before implantation was 0.87±0.63, the difference of visual acuity before and every time points after implantation was statistically significant ( F=1.434, P<0.001). The difference of visual acuity at each time point after treatment was not statistically significant ( P>0.05). The CMT was (638.59±198.46)μm before implantation, and (297.39±135.68)μm and (198.38±79.53)μm, (305.43±158.32)μm, (287.95±97.89)μm, (236.35±95.26)μm and (204.48±93.57)μm at 1, 2, 3, 4, 5 and 6 months after implantation in order. The CMT after implantation was significantly lower than those before treatment and formed a gradually declining trend ( F=24.79, P<0.001). Macular edema recurred in 11 eyes (36.67%)during the follow-up period, and the average recurrence time was (3.27±0.65) months. No serious ocular or systemic complication occurred. Conclusion:The vitrectomy assisted with intravitreal implant of dexamethasone for macular edema and macular epiretinal membrane caused by retinal vein occlusion can reduce macular edema and improve visual acuity.